ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Improved GPCR Ligands Based on Genetically Impossible Nanobody-Peptide Fusions

preprint
submitted on 14.08.2019, 15:59 and posted on 15.08.2019, 14:32 by Ross Cheloha, Fabian A. Fischer, Andrew W. Woodham, Eileen Daley, Naomi Suminski, Thomas J. Gardella, Hidde L. Ploegh
Here we describe a new method for improving signalling potency and selectivity for suboptimal GPCR ligands through conjugation with receptor-targeting nanobodies

History

Email Address of Submitting Author

ross.cheloha@gmail.com

Institution

Boston Children's Hospital/Harvard Medical School

Country

USA

ORCID For Submitting Author

0000-0001-9871-8333

Declaration of Conflict of Interest

HLP, RWC and TJG have filed a provisional patent covering this work

Exports

Logo branding

Exports